No Data
No Data
Nuvalent Doses First Subject in Phase Ia/Ib Trial of Lung Cancer Treatment
Express News | Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment
Express News | Nuvalent Announces First Patient Dosed in Heroex-1 Phase 1a/1B Clinical Trial of Nvl-330, Its Novel Her2-Selective Inhibitor
Nuvalent Insider Sold Shares Worth $403,621, According to a Recent SEC Filing
Express News | Nuvalent To Present Updated Data From ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And ALKOVE-1 Phase 1/2 Clinical Trial Of NVL-655 at ESMO Congress 2024
Express News | Nuvalent Announces Promotion of Henry Pelish, Ph.d. to Chief Scientific Officer